Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L9/00—Disinfection, sterilisation or deodorisation of air
  • A61L9/01—Deodorant compositions
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
  • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
  • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
  • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
  • A01N47/34—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the groups, e.g. biuret; Thio analogues thereof; Urea-aldehyde condensation products
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents

Definitions

• Arthropod ectoparasites commonly infecting warm-blooded animals include ticks, mites, lice, fleas, blowflies, the ectoparasite Lucilia sp. of sheep, biting insects including keds ( Melophagus ovinus ) and migrating dipterous larvae such as Hypoderma sp. and Dermatobia in cattle, Gastrophilus in horses and Cuterebra sp. in rodents, dogs and cats. Metaflumizone, amitraz and demiditraz are useful for the prevention and control of ectoparasiticide infestations in warm-blooded animals. Topical administration is a preferred method for administration of these ingredients.
• the present invention provides an improved-scent ectoparasiticidal formulation, which is stable, easy-to-apply, spreadable and minimizes animal-runoff.
• the present invention provides an improved-scent ectoparasiticidal composition, which comprises metaflumizone, fructone as the primary carrier solvent and optionally, amitraz or demiditraz. More particularly, the composition comprises metaflumizone, fructone, geranyl acetate as cosolvent and skin permeation enhancer and, optionally, additional carrier solvents and/or a bridging agent.
• the composition comprises (on a w/v basis): about 20% to about 50% fructone; about 10% to about 30% metaflumizone; about 0% to about 20% amitraz or about 0% to about 20% demiditraz; about 5% to about 15% dimethylsulfoxide (DMSO); about 5% to about 15% N,N-diethyl-m-toluamide (DEET); about 5% to about 15% ⁇ -hexylactone; about 5% to about 15% geranyl acetate; and about 1% to about 10% 1-methoxy-2-propyl acetate. More particularly, the composition comprises about 10% to about 20% w/v amitraz. Alternatively, the composition comprises about 10% to about 20% w/v demiditraz.
• Another aspect of the invention provides a method for preventing or treating an ectoparasite infestation in a warm-blooded animal, comprising, topically administering to the warm-blooded animal the improved-scent ectoparasiticidal composition.
• kits for preventing or treating an ectoparasite infestation in a warm-blooded animal comprising a topical unit dose formulation of the improved-scent ectoparasiticidal composition.
• Topical veterinary compositions containing metaflumizone, amitraz and/or demiditraz as active ingredients are highly desirable due to the effective and persistent activity of metaflumizone against a variety of ectoparasites, including, but not limited to, the dog flea, Ctenocephalides canis , and the efficacy of amitraz and demiditraz against ticks.
• the improved-scent composition of the present invention retains the desired physical characteristics over time, without loss of potency of the actives. Further, the composition of the invention exhibits sufficient viscosity to allow for the retention of the composition when applied topically to the animal's skin or hair, while facilitating the release of the ectoparasiticide(s), such as metaflumizone, amitraz and/or demiditraz, over the desired period of time.
• the ectoparasiticide(s) such as metaflumizone, amitraz and/or demiditraz
• the improved-scent composition of the present invention comprises metaflumizone and fructone as the primary carrier component.
• the composition further includes amitraz as an additional active.
• the composition further includes demiditraz as an additional active.
• the composition further comprises geranyl acetate.
• the composition further comprises at least one of a bridging agent, skin permeation enhancer and/or a carrier solvent.
• Suitable carrier solvents include ⁇ -hexylactone, N,N-diethyl-m-toluamide and 1-methoxy-2-propyl acetate.
• Suitable bridging agents are those such as, for example, dimethylsulfoxide.
• the improved-scent composition of the present invention comprises metaflumizone, fructone, geranyl acetate, and at least one, at least two, or at least three of ⁇ -hexylactone, N,N-diethyl-m-toluamide, 1-methoxy-2-propyl acetate and dimethylsulfoxide, and further optionally including amitraz and/or demiditraz.
• the metaflumizone is present at about 10% to about 40% w/v, or about 10% to about 30% w/v, or about 10% to about 20% w/v, or about 15% w/v.
• the amitraz is present at about 0% to about 20% w/v, or about 10% to about 20% w/v, or about 15% w/v.
• the demiditraz is present at about 0% to about 20% w/v, or about 10% to about 20% w/v, or about 15% w/v.
• the fructone is present at about 20% to about 60% w/v, or about 20% to about 50% w/v, or about 20% to about 40% w/v, or about 30% w/v.
• the geranyl acetate is present at about 5% to about 15% w/v, or about 7.5% to about 13% w/v, or about 10% w/v.
• ⁇ -hexylactone is present at about 5% to about 15% w/v
• N,N-diethyl-m-toluamide is present at about 5% to about 15% w/v
• 1-methoxy-2-propyl acetate is present at about 0% to about 15% w/v, or about 5% to about 15% w/v, or about 1% to about 10% w/v, or about 5% w/v.
• dimethylsulfoxide is present at about 5% to about 15% w/v, or about 10% w/v.
• the composition comprises, on a w/v basis, about 15% amitraz, about 15% metaflumizone, about 20% to about 40% fructone and about 10% geranyl acetate.
• the composition comprises, on a w/v basis, about 15% demiditraz, about 15% metaflumizone, about 20% to about 40% fructone and about 10% geranyl acetate.
• the composition comprises, on a w/v basis, about 15% to about 25% metaflumizone, about 20% to about 50% fructone and about 10% geranyl acetate.
• the composition comprises, on a w/v basis, about 10% dimethyl sulfoxide, about 10% ⁇ -hexylactone, about 10% N,N-diethyl-m-toluamide and about 5% 1-methoxy-2-propyl acetate.
• the improved-scent composition of the present invention comprises (on a w/v basis): about 20% to about 40% fructone; about 10% to about 20% metaflumizone; about 5% to about 15% DMSO; about 5% to about 15% N,N-diethyl-m-toluamide; about 5% to about 15% ⁇ -hexylactone; about 5% to about 15% geranyl acetate; and about 0% to about 10% 1-methoxy-2-propyl acetate. More particularly, the composition further comprises about 10% to about 20% amitraz. Alternatively, the composition further comprises about 10% to about 20% demiditraz.
• the composition consists essentially of (on a w/v basis), about 25% to about 35% fructone, about 15% amitraz; about 15% metaflumizone, about 10% dimethylsulfoxide. about 10% N,N-diethyl-m-toluamide, about 10% ⁇ -hexlactone, about 10% geranyl acetate and about 5% 1-methoxy-2-propyl acetate.
• the composition consists essentially of (on a w/v basis), about 25% to about 35% fructone, about 15% demiditraz, about 15% metaflumizone, about 10% dimethylsulfoxide, about 10% N,N-diethyl-m-toluamide, about 10% ⁇ -hexylactone, about 10% geranyl acetate and about 5% 1-methoxy-2-propyl acetate.
• composition comprising, on a w/v basis, about 25% to about 50% fructone; about 10% to about 30% metaflumizone; about 5% to about 15% DMSO; about 5% to about 15% N,N-diethyl-m-toluamide; about 5% to about 15% ⁇ -hexylactone; about 5% to about 15% geranyl acetate; and 0% to about 10% 1-methoxy-2-propyl acetate.
• Another aspect of the invention provides a method for preventing or treating an ectoparasite infestation in a warm-blooded animal, comprising, topically administering to the warm-blooded animal the improved-scent composition described herein. More particularly, said composition is administered in one or more spots or discrete areas on the back of the warm-blood animal.
• the ectoparasiticide is applied to the animal in 1, 2, 3, 4, or 5 locations (spots), preferably down the back of the animal or at the base of the neck.
• the warm-blooded animal is a dog. More particular still, the dog receives about 15 mg/kg to about 25 mg/kg, preferably about 20 mg/kg of each of amitraz and metaflumizone. Alternatively, the dog receives about 15 mg/kg to about 25 mg/kg, preferably about 20 mg/kg of each of demiditraz and metaflumizone.
• Another aspect of the invention provides a method for preventing or treating an ectoparasite infestation in a warm-blooded animal, comprising administering a diluted form of the improved-scent composition as a pour-on. More particularly, the diluted form of the improved-scent composition comprises about 1% to about 95% of the improved-scent composition described herein and at least one other solvent.
• kits for preventing or treating an ectoparasite infestation in a warm-blooded animal comprising a topical unit dose formulation of the improved-scent composition described herein.
• the warm-blooded animal is a cat. In a still further embodiment, the warm-blooded animal is a farm animal. In another embodiment, the warm-blooded animal is a horse.
• the bridging agent is selected from the group consisting of an alkyl methylsulfoxide, e.g. dimethylsulfoxide, decylmethyl sulfoxide or tetradecylmethylsulfoxide, a pyrrolidone, e.g., 2-pyrrolidone, N-methyl-2-pyrrolidone or N-(2-hydroxyethyl)pyrrolidone, a laurocapram, acetone, dimethyl acetamide, dimethylformamide, and tetrahydrofurfuryl alcohol.
• the bridging agent is selected from the group consisting of an L-amino acid, dimethylsulfoxide (DMSO) and a fatty acid.
• the surfactant is an anionic or cationic surfactant, a non-ionic surfactant, alcohol alkoxylate, or a nonylphenol ethoxylate.
• the composition comprises a diluent, an adjuvant, an excipient, a preservative, or a vehicle with which the active (e.g. metaflumizone and/or amitraz or demiditraz) is administered.
• the composition includes petroleum oil, animal oil, vegetable oil, peanut oil, soybean oil, mineral oil, and sesame oil.
• the composition does not comprise eucalyptol.
• the composition further comprises a preservative selected from the group consisting of methylparaben, propylparaben, thiomersal, and EDTA.
• Bridging agents that are suitably employed in the compositions disclosed herein include, without limitation, alkyl methyl sulfoxides (such as dimethylsulfoxide (DMSO), decylmethyl sulfoxide and tetradecylmethyl sulfoxide); pyrrolidones (such as 2-pyrrolidone, N-methyl-2-pyrrolidone and N-(2-hydroxyethyl)pyrrolidone); laurocapram; and miscellaneous solvents such as acetone, dimethyl acetamide, dimethyl formamide, and tetrahydrofurfuryl alcohol.
• Other bridging agents include amphiphiles such as L-amino acids, and fatty acids. Additional bridging agents are disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition (1995), on page 1583.
• carrier refers to a diluent, adjuvant, excipient, preservative, and/or vehicle with which a compound or composition is administered.
• Carrier solvents that may be suitably employed in the composition of the invention include single solvents, or a mixture of two or more solvents.
• the carrier solvents Preferably, the carrier solvents have minimal odor or mask odors of other agents. Due to the instability of metaflumizone and amitraz in the presence of primary alcohols, preferred solvents are non-hydroxyl-group-containing solvents. Surprisingly, the use of fructone as a carrier solvent provides optimum formulation properties while minimizing odors.
• ⁇ -hexylactone also known as ⁇ -caprolactone; ethyl butyrolactone; ⁇ -ethyl-n-butyrolactone; hexanolide-1, 4; 4-hydroxy hexanoic acid ⁇ -lactone or tonkalide
• ⁇ -hexylactone, ⁇ -butyrolactone etc. Synperonic NCA 830, can be employed.
• solvents such as N,N-diethyl-m-toluamide, dimethyl isosorbide, diisopropyl adipate and/or 1-methoxy-2-propyl acetate may be advantageously utilized in combination with the fructone, ⁇ -hexylactone to comprise the carrier solvent mixture.
• suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin, 18 th Edition.
• the terms “about” and “approximately” designate that a value is within a statistically meaningful range. Such a range can be typically within 10%, more typically still within 5%, and even more typically within 2% of a given value or range. The allowable variation encompassed by the terms “about” and “approximately” depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art.
• w/v designates weight of component/volume of composition
• mg/kg designates milligrams per kilogram of body weight
• a.i.” or ai designates active ingredient, and may be combined with other terms.
• mg a.i./kg designates milligrams of active ingredient per kilogram of body weight.
• the term “treating” or “treatment” of a condition includes inhibiting an existing condition or arresting its development; or ameliorating or causing regression of the condition.
• the term “preventing” or “prevention” of a condition, such as an ectoparasite infestation includes substantially blocking or inhibiting the development or growth of a condition before it starts. Compositions that treat or prevent infestations herein will preferably exhibit at least 90% efficacy.
• ectoparasiticide refers to an agent that is capable of preventing, reducing or eliminating ectoparasite infestations.
• Preferred ectoparasiticides of the present, invention include metaflumizone, amitraz, demiditraz, fipronil, pyriprole, dinotefuran and imidacloprid.
• organoleptic refers to the sensory properties of a particular composition, particularly the smell, taste, colour, and feel of the composition. Improved or enhanced organoleptic properties of ectoparasiticidal compositions, as used herein, generally refers to reduced scent or a favorable scent.
• Metaflumizone is known in the art by its chemical name: (E,Z)-2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(tri-fluoromethoxy)-phenyl]hydrazinecarboxamide and is described in U.S. Pat. No. 5,543,573.
• the chemical structure of metaflumizone is shown below:
• ProMeris® is the trade name for the veterinary formulation of metaflumizone (plus amitraz for dogs) marketed by Fort Dodge Animal Health (Wyeth, now Pfizer).
• Demiditraz is known in the art by its chemical name: 2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole and is described in Example 58 of U.S. Publication No. 2007/0167506.
• metaflumizone and optionally amitraz and/or demiditraz may be dissolved in the carrier solvent or solvents and bridging agent, and the surfactant, if desired, added to the carrier solvent solution.
• These compositions may then be utilized for spot-on topical application or may be further diluted for alternative uses.
• Compositions are most suitably formulated as creams, gels, solutions, or in microspheres.
• Improved-scent ectoparasiticidal compositions of the invention may further comprise other agents known in the art, such as preservatives (e.g., methylparaben and propylparaben), colorants, antioxidants, or the like. Generally, these agents are present in the composition in an amount up to about 2% on a weight to volume basis. Preservatives may include, for example, thiomersal, EDTA, or the like.
• Suitable exemplary polymers (“polymeric agents”) for gelling and/or adhering that may be used in the compositions of the invention include, but are not limited to, colloidal silicone dioxide, ethyl cellulose, methyl cellulose, methacrylic esters copolymers, carboxylated vinyl acetate terpolymer, Resyn® 29-2930, and polyvinylpropylene (PVP)/Vinyl acetate copolymers.
• “Gantrez”® is the trade name for a family of polyvinylmethylether formulations (as solutions, creams, powders, etc.) manufactured by International Specialty Products, of Wayne, N.J. Gantrez powder formulations comprise poly(vinylmethylether/maleic anhydride).
• Gantrez cream formulations comprise ethyl or butyl esters of polyvinylmethylether/maleic anhydride copolymer and ethyl or butyl esters of PVM/MA copolymer.
• Resyn® 29-2930 is the trade name for vinyl acetate/crotanoates/vinylneodecanoate copolymer.
• Carbopol® is the trade name of exemplary carbomers used in the formulation of certain embodiments of the presently disclosed compositions. Acrylic acid polymers other than—or in addition to—carbomers are also contemplated for use in the present invention.
• compositions are formulated as microspheres
• polymers including, but not limited to, sulfopolyester (AQ55S polymer from Eastman Chemical Co., Kingsport, Tenn., USA; typical repeating units of these polymers are disclosed in column 7 of U.S. Pat. No. 5,260,052.
• sulfopolyester AQ55S polymer from Eastman Chemical Co., Kingsport, Tenn., USA; typical repeating units of these polymers are disclosed in column 7 of U.S. Pat. No. 5,260,052.
• CAB cellulose acetate butyrate
• PLGA poly(lactide-co-glycolide)
• microsphere formulation may employ one or more of polylactic galactide, hollow microspheres such as Expancel (Nobel Industrie), Polytrap (Dow Corning), and hollow silica microspheres (Silica Beads from Maprecos).
• UV-absorbing compounds may be included in the compositions and formulations of the present invention.
• the ectoparasiticidal topical veterinary composition of the invention allows for administration of active ingredients and demonstrates no irritation and minimal adverse scent to the skin/hide/hair of the host animal with reduced and improved organoleptic properties.
• the improved-scent ectoparasiticidal composition of the invention is effective for preventing or mitigating ectoparasitic infection and/or infestation for prolonged periods of time in Warm-blooded animals such as swine, cattle, sheep, horses, goats, camels, water buffalo, bison, donkeys, rabbits, kangaroos, fallow deer, reindeer, minks, chinchillas, raccoons, chicken, geese, turkeys, ducks, dogs, cats, or the like, preferably dogs, cats, swine, cattle, horses or sheep, and most preferably dogs.
• Warm-blooded animals such as swine, cattle, sheep, horses, goats, camels, water buffalo, bison, donkeys, rabbits, kangaroos, fallow deer, reindeer, minks, chinchillas, raccoons, chicken, geese, turkeys, ducks, dogs, cats, or
• topical administrations suitable for use in the method of the invention include spot-on, pour-on, dip, wash, shampoo, foam, gel, lotion, cream, microsphere-encapsulated formulation, powder, or any of the conventional means of topically applying a liquid or semi-liquid veterinary composition.
• the topical mode of administration will vary with the species and size of the host animal.
• the composition of the present invention is administered as a spot-on formulation to a dog.
• Ectoparasitic infection or infestations suitable for treatment by the methods of the invention include fleas, ticks, lice, mites and flies.
• the methods and kits of the present invention are suitable for treating or preventing flea infestations, and even more particularly, infestations of the dog flea, Ctenocephalides canis and tick infestations.
• composition of the invention may be administered in dose rates of mg of active ingredient per kg of body weight of the host animal.
• dose rates suitable for use in the method of invention will vary depending upon the identity of the ectoparasiticide, the mode of administration, the species and health of the host animal, the target parasite, the degree of infection or infestation, the breeding habitat, the potency of the additional parasiticidal compound, or the like.
• Typical “spot-on” applications of exemplary embodiments of the invention are applied to the base of the neck of the animal or generally along the dorsal midline in the area between the shoulder blades, so as to aid in making the applied composition difficult for the animal to remove.
• Composition A A:
• compositions are prepared according to the general procedure described fro composition A.
• Composition B is a composition of Composition B:
• Composition C is a composition having Composition C:
• Composition D is a composition of Composition D:
• Metaflumizone canine Flea only Spot-On Volume to be applied per 10 kg body weight INGREDIENTS Quantities (% w/v) Metaflumizone ⁇ 25.50 (100% pure) N,N-Diethyl-m-toluamide 13.8 Dimethyl sulfoxide 10.0 1-Methoxy-2-propyl 5.00 acetate Geranyl acetate 10.0 ⁇ -Hexalactone 10.0 Fructone q.s. ad (35.3) Density (g/mL) 1.096 ⁇ Contains 2% overage.
• Composition E is a composition of Composition E:
• Composition M is a composition of Composition M:
• Composition N is a composition of Composition N:
• the organoleptic studies were performed on different compositions to determine the acceptability of the formulation's perceived odor in comparison to that of the original ProMeris® for dog spot-on.
• composition G scored the highest aggregate of 248, which means it had the most acceptable odor. Also, zero people out of 40 scored it as the worst smelling formulation. Composition G contained high levels of fructone, which was observed to have a fruity odor.
• Organoleptic test was performed on different variations of the preferred composition (G) from test 1, with geranyl acetate and orange flower ether evaluated as possible partial replacements for 1-Methoxy-2-propyl acetate. 36 persons employed by Wyeth volunteered to take part in organoleptic test 2.
• composition A scored a highest aggregate of 158.
• Compositions A and B were tested for efficacy to determine if the new spot-on formulations are as efficacious as ProMeris® for controlling existing infestation and weekly challenges of flea and tick infestations on mixed breed dogs. Results showed that all dogs presented normal health and behavior throughout the course of study. Flea counts indicated that efficacy rates against infestation for Compositions A, B, and ProMeris® for Dogs, were not statistically different and ⁇ 98.8% on all time points evaluated after treatment up to Day 42. In regards to tick counts, geometric means were not statistically different between Compositions A, B, and ProMeris® for Dogs and ⁇ 97.3% on all times evaluated after treatment up to Day 28. On study day 35, efficacy rate for Composition B dropped below 90% and was significantly lower than Composition A and ProMeris® for Dogs.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Plant Pathology (AREA)
• Pest Control & Pesticides (AREA)
• Agronomy & Crop Science (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=42132662

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (8)

Citations (3)

Family Cites Families (5)

• 2010
  • 2010-02-19 MX MX2011008816A patent/MX2011008816A/es active IP Right Grant
  • 2010-02-19 BR BRPI1008403-7A patent/BRPI1008403A2/pt not_active IP Right Cessation
  • 2010-02-19 CA CA2751038A patent/CA2751038A1/fr not_active Abandoned
  • 2010-02-19 KR KR1020117019472A patent/KR20110106943A/ko not_active Application Discontinuation
  • 2010-02-19 AU AU2010215994A patent/AU2010215994A1/en not_active Abandoned
  • 2010-02-19 EP EP10704724A patent/EP2398318B1/fr not_active Not-in-force
  • 2010-02-19 WO PCT/US2010/024677 patent/WO2010096623A1/fr active Application Filing
  • 2010-02-19 US US13/146,963 patent/US20120041042A1/en not_active Abandoned
  • 2010-02-19 NZ NZ594259A patent/NZ594259A/xx not_active IP Right Cessation
  • 2010-02-19 CN CN201080008765XA patent/CN102325448A/zh active Pending
  • 2010-02-22 JP JP2010035878A patent/JP2010195781A/ja not_active Withdrawn
  • 2010-02-22 AR ARP100100507A patent/AR075537A1/es not_active Application Discontinuation
• 2011
  • 2011-07-21 ZA ZA2011/05383A patent/ZA201105383B/en unknown

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events